Meet the Director
"The Experimental Therapeutics Institute enables Mount Sinai to integrate the many facets of therapeutics research, including small-molecule drugs and gene- and cell-based therapeutics to evaluate and develop therapeutics for complex diseases."
Scott L. Friedman, MD
Dean For Therapeutic Discovery, Fishberg Professor of Medicine, Professor of Pharmacology and Systems Therapeutics, and Chief of the Division of Liver Diseases
Scott L. Friedman, MD, is founding Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at Icahn School of Medicine at Mount Sinai. He performed pioneering research that isolated and characterized the hepatic stellate cell, the key cell type responsible for scar production in liver. This achievement spawned an entire field that is now realizing its translational and therapeutic potential, with new anti-fibrotic therapies for liver disease reaching clinical trials. In this capacity Dr. Friedman interacts widely with the Biotech and Pharmaceutical industries in drug discovery and development, and clinical trial design. Dr. Friedman’s work has been continuously funded by the National Institutes of Health since 1985; he has held many national leadership positions including President of the American Association for the Study of Liver Diseases, Senior Fulbright Fellow at the Weizmann Institute of Science, and Senior Advisory Council for the National Institute of Alcohol Abuse and Alcoholism. He has published over 250 scientific articles, and is among the most preeminent scholars in his field worldwide.
Louise Lammers, PhD
Associate Director Operations
Experimental Therapeutics Institute
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1675
1425 Madison Avenue
New York, NY 10029-6574